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ABSTRACT; 
Background; Insulin resistance has been implicated in the pathogenesis of both nonalcoholic fatty liver disease 
(NAFLD) and polycystic ovary syndrome (PCOS) and different studies documented the role of polycystic 
ovarian syndrome in development of non – alcoholic fatty liver disease (NAFLD) So this study was conducted in 
our population to ascertain its frequency in our population as there is no study done in our local poulation. 
Material and Methods; This cross – sectional study was conducted at Department of Obstetrics and 
Gyncecology, Nishtar Hospital, Multan using non – probability consecutive sampling technique. A total of 117 
women with PCOs were included in our study which underwent relevant investigations for NAFLD. All the data 
obtained was entered and analyzed by SPSS – 16. Results; Mean age of our study cases was 31.35 ± 5.67 years. 
Our study results have indicated that majority of our study cases i.e. 62 (53%) were aged up to 30 years. Of these 
117 study cases, 50 (42.7%) belonged to rural areas while 67 (57.3%) from urban areas, 61 (52.1%) were poor 
and 56 (47.9%) belonged to middle income families. Of these 117 study cases, 91 (77.8%) were married and 77 
(65.8%) had parity up to 3. Mean body mass index (BMI) of our study cases was 26. 43 ± 3.11 kg/m2 and obesity 
was present in 41 (35%) of our study cases. Mean disease duration was 10.22 ± 6.39 months and disease 
duration up to 12 months was present in 74 (63.2%). Mean ALT of our study cases was noted to be 42.97 ± 
23.74 IU/L and non – alcoholic fatty liver disease was present in 57 (48.7%) of our study cases. Conclusion; 
Very high frequency of non – alcoholic fatty liver disease (NAFLD) was observed in patients having polycystic 
ovarian syndrome in our study. NAFLD was significantly associated with age, parity, obesity and prolonged 
disease duration. All the clinicians who are treating patients of Polycystic Ovarian syndrome must screen them 
for liver disease due to its high burden in these patients for early management which will decrease disease 
morbidity and will also improve their quality of life.  
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INTRODUCTION 
Polycystic ovary syndrome (PCOS) is one of the most common endocrinological disorders, affecting 5–10% of 
the population of women in reproductive age1.  Nowadays, PCOS is accepted to be not only a gynecological 
disorder, but also include cardiovascular risk factors and several metabolic problems
2
. Existing data indicate that 
about 50% of patients with PCOS have insulin resistance and fulfil the criteria for metabolic syndrome
3
.  
Journal of Medicine, Physiology and Biophysics                                                                                                                              www.iiste.org 
ISSN 2422-8427     An International Peer-reviewed Journal 
Vol.41, 2018 
 
45 
Although the pathophysiology of PCOS is not fully understood, insulin resistance (IR) seems to play a key role 
in the development of PCOS
3,4
. Nonalcoholic fatty liver disease (NAFLD) is now recognized as one of the most 
common causes of chronic liver disease in western countries. Pathologically, NAFLD comprises various degrees 
of progressive steatosis, lobular inflammation, and fibrosis of the liver
5
.  NAFLD is strongly associated with 
insulin resistance, which is thought to have a key role in its pathogenesis and progression. Moreover, considering 
that a high proportion of patients exhibit the cluster of risk factors that defines metabolic syndrome, NAFLD is 
considered the hepatic manifestation of metabolic syndrome6. Considering the high prevalence of insulin 
resistance in PCOS, a ‘hepatic manifestation’ of PCOS might be speculated7.  In fact, there is evidence from 
small cohorts showing that PCOS women are at an increased risk of developing NAFLD and conversely women 
with NAFLD are at an increased risk of having PCOS
8,9
. Another consideration is that insulin resistance is a 
common feature of both NAFLD and PCOS, it is very likely that both entities coexist in a given patient. This is 
an important issue which may have relevance for clinical management in terms of when and how to screen for 
liver disease in patients with PCOS. However, data on this issue are scarce
10,11
. In a study by Cedra C, et al, 
compared the frequency of NAFLD among patients with PCOS and controls. They found that Patients with 
PCOS showed a higher frequency of NAFLD (41% vs. 19%) than a control group. This suggests that patients 
with PCOS may have NAFLD, which is not addressed by treating gynaecologists or endocrinologists routinely. 
Since, there exist no recent guidelines regarding screening of NAFLD among patients with PCOS. So, this issue 
may remain unaddressed and may get complicated by liver cirrhosis and failure  
 
MATERIALS AND METHODS 
All patients of PCOs aged 20 – 45 years, duration of PCOs atleast 6 months were included in this study 
irrespective of their marital status and parity. Patients having history of alcohol use, hepatotoxic drugs like 
antituberculous, antifungal etc, hepatocellular malignancy and hepatitis A, B, or C virus infection were excluded 
from our study.  
One hundred and seventeen cases fulfilling inclusion criteria were registered through outpatient Department of 
Gynaecology and Obstetrics, Nishtar Hospital Multan. Demographic history [including age (in years) was taken. 
Informed consent was taken through patients. Ultrasonography and serum ALT levels were sent for the detection 
of NAFLD in all the patients. The patients was labeled as yes for NAFLD if detected on USG and raised ALT 
levels more than 45 IU/L. All the collected data was entered into SPSS version 20 and analyzed.  
 
RESULTS; 
Our study comprised of a total of 117 study cases with polycystic ovarian syndrome who met inclusion 
criteria of our study. Mean age of our study cases was 31.35 ± 5.67 years (with minimum age of our study cases 
was 23 years while maximum age was 44 years). Our study results have indicated that majority of our study 
cases i.e. 62 (53%) were aged up to 30 years. Of these 117 study cases, 50 (42.7%) belonged to rural areas while 
67 (57.3%) from urban areas, 61 (52.1%) were poor and 56 (47.9%) belonged to middle income families. Of 
these 117 study cases, 91 (77.8%) were married and 77 (65.8%) had parity up to 3. Mean height of our study 
cases was 157.44 ± 13.37 centimeters while mean weight of our study cases was 68.48 ± 12.91 kilograms. Mean 
body mass index (BMI) of our study cases was 26. 43 ± 3.11 kg/m2 and obesity was present in 41 (35%) of our 
study cases. Mean disease duration was 10.22 ± 6.39 months and disease duration up to 12 months was present 
in 74 (63.2%). Mean ALT of our study cases was noted to be 42.97 ± 23.74 IU/L and non – alcoholic fatty liver 
disease was present in 57 (48.7%) of our study cases.  
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Table No. 1 Stratification of Non – alcoholic fatty liver disease (NAFLD) with regards to obesity.  
Obesity 
NAFLD 
P – value  Yes 
(n = 57) 
No 
(n = 60) 
Yes 
(n = 41) 
36 05 
0.000 
No 
(n = 76) 
21 55 
 
Total 
 
117 
 
Table No. 2 
Stratification of Non – alcoholic fatty liver disease (NAFLD) with regards to disease duration.  
(n = 117) 
Disease duration 
NAFLD 
P – value  Yes 
(n = 57) 
No 
(n = 60) 
Up to 12 months 
(n = 74) 
25 49 
0.001 
More than 12 months 
(n = 43) 
32 11 
 
Total 
 
117 
 
DISCUSSION; 
Polycystic ovary syndrome (PCOS) is a common heterogeneous endocrine disorder characterized by 
irregular menses, hyperandrogenism, and polycystic ovaries12, 13. Although not required for diagnosis, the 
presence of insulin resistance and hyperinsulinemia is common and places those affected at increased risk of 
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diabetes and cardiovascular disease. Thus, PCOS adversely affects endocrine, metabolic, and cardiovascular 
health 
14, 15
. 
Our study comprised of a total of 117 study cases with polycystic ovarian syndrome who met inclusion 
criteria of our study. Mean age of our study cases was 31.35 ± 5.67 years (with minimum age of our study cases 
was 23 years while maximum age was 44 years). Our study results have indicated that majority of our study 
cases i.e. 62 (53%) were aged up to 30 years. A study conducted by Wahab et al 
 16  
from Peshawar also reported 
27 ± 5.2 years mean age in women with PCOs which is close to our study results. Another study conducted by 
Butt et al 
 17 
from Lahore also reported 30 ± 5.77 years mean age of the patients with PCOs which is close to our 
study results. Fauzia et al 
 18 
from Hyderabad reported 57 % patients with PCOs belonged to the age group of 21 
– 30 years which is in compliance with our study results. Wagan et al 
 19 
from Nawabshah also reported 24.49 ± 
4.87 years mean age which is in compliance with our study results. Another study from Abbottabad by Abbasi et 
al  20 also reported PCOs were predominately more present in women aged less than 35 years of age which is in 
compliance with our study results.  
Of these 117 study cases, 50 (42.7%) belonged to rural areas while 67 (57.3%) from urban areas, 61 
(52.1%) were poor and 56 (47.9%) belonged to middle income families. Of these 117 study cases, 91 (77.8%) 
were married and 77 (65.8%) had parity up to 3. Mean height of our study cases was 157.44 ± 13.37 centimeters 
while mean weight of our study cases was 68.48 ± 12.91 kilograms. Mean body mass index (BMI) of our study 
cases was 26. 43 ± 3.11 kg/m
2 
and obesity was present in 41 (35%) of our study cases. A study conducted by 
Usmani et al  21 from Karachi also reported 25.6 ± 4.7 kg/m2 BMI of the patients with PCOs which is close to our 
study results. Nisa et al  22 from Saudi Arabia also reported similar results.  
Mean disease duration was 10.22 ± 6.39 months and disease duration up to 12 months was present in 74 
(63.2%). Mean ALT of our study cases was noted to be 42.97 ± 23.74 IU/L and non – alcoholic fatty liver 
disease was present in 57 (48.7%) of our study cases. Zheng et al  23 from China reported 42 % NAFLD in 
patients with PCOs which is close to our study results. A study conducted in Greece by Vassilatou et al  24  also 
reported 64.5 % NAFLD in PCOs which is in compliance with our study results.  
 
CONCLUSION; 
Very high frequency of non – alcoholic fatty liver disease (NAFLD) was observed in patients having polycystic 
ovarian syndrome in our study. NAFLD was significantly associated with age, parity, obesity and prolonged 
disease duration. All the clinicians who are treating patients of Polycystic Ovarian syndrome must screen them 
for liver disease due to its high burden in these patients for early management which will decrease disease 
morbidity and will also improve their quality of life.  
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